Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States.

Talha Munir,Victoria Genovez,Victor Genestier,Kellie Ryan,Bengt Liljas,Priyanka Gaitonde

Expert review of pharmacoeconomics & outcomes research（2023）

引用 2|浏览2

暂无评分

摘要

Although the analysis is limited by uncertainty in postprogression survival outcomes, acalabrutinib monotherapy is likely cost-effective vs chlorambucil + obinutuzumab in treatment-naive CLL in the US Medicare setting.

查看译文

关键词

Bruton tyrosine kinase inhibitors,chronic lymphocytic leukemia,cost-effectiveness analysis,cost-utility analysis,health care costs

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要